Lloyd E Damon
Overview
Explore the profile of Lloyd E Damon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliai C, Park S, Damon L, Jonas B, Jeyakumar D, Wieduwilt M, et al.
Leuk Lymphoma
. 2024 Dec;
1-7.
PMID: 39689718
In this multicenter phase Ib trial, we investigated the combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory acute myeloid leukemia (AML). Cohort A received CPX-351 plus a single dose...
2.
Huang L, Shi Y, Andreadis C, Logan A, Mannis G, Smith C, et al.
J Geriatr Oncol
. 2023 Sep;
14(8):101623.
PMID: 37678052
Introduction: Allogeneic hematopoietic cell transplantation (alloHCT) is increasingly offered to older adults, and its potential impact on cognition in this population is understudied. This work aims to evaluate the ability...
3.
Huang L, Sheng Y, Andreadis C, Logan A, Mannis G, Smith C, et al.
Transplant Cell Ther
. 2022 Mar;
28(6):309.e1-309.e9.
PMID: 35247612
As allogeneic hematopoietic cell transplantation (alloHCT) is increasingly offered to older adults, geriatric assessment (GA) has been identified as a useful tool for predicting outcomes, particularly functional status. However, very...
4.
Schuster S, Tam C, Borchmann P, Worel N, McGuirk J, Holte H, et al.
Lancet Oncol
. 2021 Sep;
22(10):1403-1415.
PMID: 34516954
Background: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the...
5.
Wang V, Blaser B, Patel R, Behbehani G, Rao A, Durbin-Johnson B, et al.
Blood Cancer Discov
. 2021 Sep;
2(5):434-449.
PMID: 34514432
Acute myeloid leukemia patients refractory to induction therapy or relapsed within one year have poor outcomes. Autocrine production of hepatocyte growth factor by myeloid blasts drives leukemogenesis in pre-clinical models....
6.
Nawas M, Sheng Y, Huang C, Andreadis C, Martin T, Wolf J, et al.
J Geriatr Oncol
. 2020 Oct;
12(4):531-539.
PMID: 33059999
Objectives: We sought to examine the natural history of geriatric assessment (GA) and quality of life (QOL) domains among adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation (autoHCT)....
7.
Shah E, Young R, Wong S, Damon L, Wolf J, Shah N, et al.
Biol Blood Marrow Transplant
. 2019 Dec;
26(5):876-883.
PMID: 31785375
Patients with multiple myeloma (MM) scheduled for autologous stem cell transplantation must undergo autologous stem cell mobilization; unfortunately, however, many do not obtain an adequate collection yield. Despite the availability...
8.
Huang L, Sheng Y, Andreadis C, Logan A, Mannis G, Smith C, et al.
Biol Blood Marrow Transplant
. 2019 Sep;
26(1):189-196.
PMID: 31493541
Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated...
9.
Wieduwilt M, Pawlowska N, Thomas S, Olin R, Logan A, Damon L, et al.
Clin Cancer Res
. 2019 Jun;
25(16):4917-4923.
PMID: 31152020
Purpose: The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. We hypothesized that panobinostat prior to and during induction chemotherapy would be...
10.
Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al.
Lancet Haematol
. 2019 Mar;
6(3):e132-e143.
PMID: 30824040
Background: Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation...